{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'Table 8', 'Summary of Predicted Mean Response and Mean >Grade 2 Corneal', 'Event* and 95% Credible Intervals (Parts 1 and 2, Study BMA117159)', 'Predicted response rate (%)', 'Predicted >G2 corneal AE rate', 'Dose (mg/kg)', '(95% credible interval)', '(%) (95% credible interval)', '1.92', '25.3 (9.4, 42.2)', '33.7 (18.3, 49.0)', '2.5', '37.0 (22.3, 51.6)', '43.4 (30.2, 56.9)', '3.4', '53.7 (40.3, 66.9)', '55.7 (42.3, 68.7)', '*Predicted values are based on the posterior distribution of response rate and corneal event rate per', 'CTCAE 4.03', 'In summary, based on the safety, tolerability, and clinical activity observed to date,', '2.5 mg/kg and 3.4 mg/kg were selected as the appropriate dose levels of GSK2857916 to', 'be further studied in this phase 2 study. The dose may be further individually adjusted in', 'participants experiencing adverse events, according to the guidance in the protocol.', '6.', 'STUDY POPULATION', 'Prospective approval of protocol deviations to recruitment and enrollment criteria, also', 'known as protocol waivers or exemptions, are not permitted.', '6.1.', 'Inclusion Criteria', 'Participants are eligible to be included in the study only if all of the following criteria', 'apply:', '1. Provide signed written informed consent, which includes compliance with the', 'requirements and restrictions listed in the consent form', '2.', 'Male or female, 18 years or older (at the time consent is obtained)', '3.', 'Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (Appendix', '8)', '4. Histologically or cytologically confirmed diagnosis of MM as defined according to', 'IMWG, [Rajkumar, 2014] criteria, and', 'a) Has undergone stem cell transplant or is considered transplant ineligible, and', 'b) Has failed at least 3 prior lines of anti-myeloma treatments, including an anti-', 'CD38 antibody (e.g., daratumumab) alone or in combination, and is refractory to', 'an IMiD (i.e., lenalidomide or pomalidomide), and to a proteasome inhibitor', '(e.g., bortezomib, ixazomib or carfilzomib). The number of prior lines of', 'therapy will be determined according to the guidelines in Rajkumar, 2015.', 'Refractory myeloma is defined as disease that is nonresponsive while on', 'primary or salvage therapy, or progresses within 60 days of last therapy.', 'Nonresponsive disease is defined as either failure to achieve at least minimal', 'response or development of progressive disease (PD) while on therapy', '[Rajkumar, 2011]', '51']['2017N330177_04', 'CONFIDENTIAL', '205678', '5.', 'Has measurable disease with at least one of the following:', 'a.', 'Serum M-protein >0.5 g/dL(>5 g/L)', 'b.', 'Urine M-protein >200 mg/24h', 'c.', 'Serum FLC assay: Involved FLC level >10 mg/dL (>100 mg/L) and an', 'abnormal serum free light chain ratio (<0.26 or > -1.65)', '6. Participants with a history of autologous stem cell transplant are eligible for study', 'participation provided the following eligibility criteria are met:', 'a.', 'transplant was >100 days prior to study enrolment', 'b.', 'no active infection(s)', 'c. participant meets the remainder of the eligibility criteria outlined in this protocol', '7.', 'Adequate organ system functions as defined in Table 9.', 'Table 9', 'Criteria for Determining Adequate Organ System Function', 'System', 'Laboratory Values', 'Hematologic', 'Absolute neutrophil count (ANC)', '>1.0 X 10%/L', 'Hemoglobin', '>8.0 g/dL', 'Platelets', '>50 X 10%/L', 'Hepatic', 'Total bilirubin', '<1.5X ULN', '(Isolated bilirubin >1.5xULN is acceptable if bilirubin is', 'fractionated and direct bilirubin <35%)', 'ALT', '<2.5 X ULN', 'Renal', 'eGFRa', '>30 mL/min/ 1 1.73 m\u00b2', 'Spot urine (albumin/creatinine ratios (spot urine)', '<500 mg/g (56 mg/mmol)', 'Cardiac', 'LVEF (Echo)', '>45%', 'a.', 'As calculated MDRD equation (Appendix 10)', 'Note: Laboratory results obtained during Screening must be used to determine eligibility criteria. In situations', 'where laboratory results are outside the permitted range, the investigator may retest the participant and the', 'subsequent within range screening result may be used to confirm eligibility.', '8.', 'Female Participants: Contraceptive use by men or women should be consistent with', 'local regulations regarding the methods of contraception for those participating in', 'clinical studies.', 'A female participant is eligible to participate if she is not pregnant or breastfeeding,', 'and at least one of the following conditions applies:', 'Is not a woman of childbearing potential (WOCBP)', 'OR', 'Is a WOCBP and using a contraceptive method that is highly effective (with a', 'failure rate of <1% per year), preferably with low user dependency, during the', 'intervention period and for at least 80 days after the last dose of study', '52']\n\n###\n\n", "completion": "END"}